Aptose Biosciences Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Interim Statements of Changes in Shareholders' Equity (Unaudited)

Condensed Consolidated Interim Statements of Changes in Shareholders' Equity (Unaudited) - USD ($) $ in Thousands	Public Offering [Member] Common Stock [Member]	Public Offering [Member]	The 2019 Share Purchase Agreement [Member] Common Stock [Member]	The 2019 Share Purchase Agreement [Member]	The 2018 ATM Offering [Member] Common Stock [Member]	The 2018 ATM Offering [Member]	The 2018 Purchase Agreement [Member] Common Stock [Member]	The 2018 Purchase Agreement [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	AOCI Attributable to Parent [Member]	Retained Earnings [Member]	Total
Balance (in shares) at Dec. 31, 2018									38,162,000
Balance at Dec. 31, 2018									$ 261,072	$ 32,963	$ (4,316)	$ (275,638)	$ 14,081
Common shares issued pursuant to the public offering (in shares)			171,000		77,000	77,349	5,502,000	5,502,433	11,500,000
Common shares issued			$ 360	$ 360	$ 178	$ 178	$ 10,000	$ 10,000	$ 19,594				$ 19,594
Common shares issued upon exercise of stock options (in shares)									34,000				34,000
Common shares issued upon exercise of stock options									$ 60	(24)			$ 36
Stock-based compensation										1,734			1,734
Common shares issued upon redemption of restricted share units (in shares)									40,000
Common shares issued upon redemption of restricted share units									$ 80	(80)
Other comprehensive gain (loss)											13		13
Net loss												(18,568)	(18,568)
Balance (in shares) at Sep. 30, 2019									55,486,000
Balance at Sep. 30, 2019									$ 291,344	34,593	(4,303)	(294,206)	27,428
Balance (in shares) at Dec. 31, 2019									76,108,000
Balance at Dec. 31, 2019									$ 365,490	34,649	(4,298)	(301,915)	$ 93,926
Common shares issued pursuant to the public offering (in shares)	11,854,000
Common shares issued	$ 58,234	$ 58,234
Common shares issued upon exercise of stock options (in shares)									215,000				215,000
Common shares issued upon exercise of stock options									$ 932	(401)			$ 531
Stock-based compensation										17,007			17,007
Common shares issued upon redemption of restricted share units (in shares)									685,000
Common shares issued upon redemption of restricted share units									$ 4,801	(4,801)
Other comprehensive gain (loss)											(17)		(17)
Net loss												(40,525)	(40,525)
Balance (in shares) at Sep. 30, 2020									88,862,000
Balance at Sep. 30, 2020									$ 429,457	$ 46,454	$ (4,315)	$ (342,440)	$ 129,156